Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Abacus Health Products, Inc.    ABCS   CA00258K1049

ABACUS HEALTH PRODUCTS, INC.

(ABCS)
  Report
SummaryQuotesNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Abacus Health Products : Receives Court Approval for Arrangement with Charlotte's Web

share with twitter share with LinkedIn share with facebook
06/08/2020 | 04:37pm EDT

Abacus Health Products, Inc. (CSE: ABCS, OTCQB:ABAHF) (“Abacus”) is pleased to announce that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving the proposed acquisition of Abacus by Charlotte’s Web Holdings, Inc. (“Charlotte’s Web”) pursuant to the previously-announced arrangement (the “Arrangement”) under the Business Corporations Act (Ontario).

The closing of the Arrangement remains subject to certain customary closing conditions. Assuming the timely satisfaction of these closing conditions, the Arrangement is expected to close on or about June 11, 2020.

Registered shareholders of Abacus who have questions or require assistance with submitting their letter of transmittal in connection with the Arrangement may contact Odyssey Trust Company, who is acting as Abacus' depositary, at 1-587-885-0960 or by email at corp.actions@odysseytrust.com.

Further information regarding the Arrangement is available in the management information circular of Abacus dated May 4, 2020 (“Information Circular”), which is available under Abacus’ profile on SEDAR at www.sedar.com and on the investor relations section of Abacus’ website at https://abacushp.com/investors/management-circular.

Forward-Looking Statements

Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities legislation. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is based on a number of assumptions and involves known and unknown risks, uncertainties and other factors which may cause the actual results and events to be materially different from those that are disclosed in or implied by such forward-looking information. The forward-looking information in this press release includes, but is not limited to, statements relating to expectations with respect to the anticipated timing of the proposed Arrangement. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

Additional information about these assumptions, risks, uncertainties and other factors is contained in Abacus’ annual information form dated April 29, 2020 and in the Information Circular, which are available under the issuer profile of Abacus on SEDAR at www.sedar.com.

Although Abacus believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release is made as of the date of this news release and Abacus does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, unless required by applicable securities laws.

There can be no assurance that the Arrangement will occur, or that it will occur on the terms and conditions contemplated in the Information Circular. The Arrangement could be modified, restructured or terminated. Actual results could differ materially from those currently anticipated due to a number of factors and risks. There can be no assurance that the Arrangement will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the Information Circular, any information released or received with respect to the Arrangement may not be accurate or complete and should not be relied upon.

About Abacus Health Products, Inc.

Abacus is principally engaged in the development and commercialization of over-the-counter (OTC) topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers three lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™ and Harmony Hemp™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by contract manufacturers, including in an FDA registered and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com

© Business Wire 2020

share with twitter share with LinkedIn share with facebook
All news about ABACUS HEALTH PRODUCTS, INC.
06/11CSE BULLETIN : Delist - Abacus Health Products Inc. (ABCS and ABCS.WT)
NE
06/11CHARLOTTE WEB : Acquires Abacus Health Products
AQ
06/08ABACUS HEALTH PRODUCTS : Receives Court Approval for Arrangement with Charlotte'..
BU
06/04ABACUS HEALTH PRODUCTS : rsquo; Shareholders Approve Arrangement with Charlotte'..
BU
05/28ABACUS HEALTH PRODUCTS : Reports First Quarter 2020 Financial Results
BU
05/25ABACUS HEALTH PRODUCTS : Announces Release Date for 2020 First Quarter Financial..
AQ
05/25ABACUS HEALTH PRODUCTS : Announces ISS and Glass Lewis Recommendations For its P..
BU
05/22ABACUS HEALTH PRODUCTS : Announces Release Date for 2020 First Quarter Financial..
BU
05/08ABACUS HEALTH PRODUCTS : Announces Special Meeting of Shareholders and Filing of..
BU
04/29ABACUS HEALTH PRODUCTS : Reports Fourth Quarter and Year-End 2019 Financial Resu..
BU
More news
Financials (USD)
Sales 2019 15,5 M - -
Net income 2019 -16,6 M - -
Net cash 2019 21,9 M - -
P/E ratio 2019 -7,01x
Yield 2019 -
Capitalization 112 M 114 M -
EV / Sales 2018 -
EV / Sales 2019 4,98x
Nbr of Employees 57
Free-Float -
Chart ABACUS HEALTH PRODUCTS, INC.
Duration : Period :
Abacus Health Products, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Perry Antelman Chairman & Chief Executive Officer
Charlie Hughes Vice President-Operations
Henry R Hague Chief Financial Officer
Bharat Madhavan Chief Technology Officer
Phillip Charles Henderson Director